A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With EGFR Mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, Following Complete Tumour Resection
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ADAURA2
- Sponsors AstraZeneca; AstraZeneca AB
- 23 Sep 2024 Status changed from recruiting to active, no longer recruiting.
- 09 Aug 2022 Trial design presented at the 2022 World Conference on Lung Cancer
- 20 Jul 2022 Planned End Date changed from 2 Nov 2032 to 1 Nov 2032.